Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear. METHODS: We randomly assigned 4822 patients with New York Heart Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening renal function, and change in Kansas City Cardiomyopathy Questionnaire [KCCQ] clinical summary score [scale, 0 to 100, with higher scores indicating fewer symptoms and physical limitations]), and safety were also assessed. RESULTS: There were 894 primary events in 526 patients in the sacubitril-valsartan group and 1009 primary events in 557 patients in the valsartan group (rate ratio, 0.87; 95% confidence interval [CI], 0.75 to 1.01; P = 0.06). The incidence of death from cardiovascular causes was 8.5% in the sacubitril-valsartan group and 8.9% in the valsartan group (hazard ratio, 0.95; 95% CI, 0.79 to 1.16); there were 690 and 797 total hospitalizations for heart failure, respectively (rate ratio, 0.85; 95% CI, 0.72 to 1.00). NYHA class improved in 15.0% of the patients in the sacubitril-valsartan group and in 12.6% of those in the valsartan group (odds ratio, 1.45; 95% CI, 1.13 to 1.86); renal function worsened in 1.4% and 2.7%, respectively (hazard ratio, 0.50; 95% CI, 0.33 to 0.77). The mean change in the KCCQ clinical summary score at 8 months was 1.0 point (95% CI, 0.0 to 2.1) higher in the sacubitril-valsartan group. Patients in the sacubitril-valsartan group had a higher incidence of hypotension and angioedema and a lower incidence of hyperkalemia. Among 12 prespecified subgroups, there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women. CONCLUSIONS: Sacubitril-valsartan did not result in a significantly lower rate of total hospitalizations for heart failure and death from cardiovascular causes among patients with heart failure and an ejection fraction of 45% or higher. (Funded by Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the PARAGON-HF trial (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction), neprilysin inhibition reduced the risk of cardiovascular death and total hospitalizations by 13%, improved KCCQ by 1.0 points, and had no overall effect on the EuroQol Visual Analog Scale.3,9”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Self-citationYusuf, S., Pfeffer, M. A., Swedberg, K., Granger, C. B., Held, P., McMurray, J. J., Michelson, E. L., Olofsson, B., & Östergren, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14285-7 · Cited by 2,994
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationIrbesartan in patients with heart failure and preserved ejection fraction
Massie, B. M., Carson, P. E., McMurray, J. J., Komajda, M., McKelvie, R., Zile, M. R., Anderson, S., Donovan, M., Iverson, E., Staiger, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805450 · Cited by 1,960
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Zile, M. R., Baicu, C. F., & Gaasch, W. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032566 · Cited by 1,563
Self-citationThe perindopril in elderly people with chronic heart failure (PEP-CHF) study
Cleland, J. G. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl250 · Cited by 1,508
Self-citationSolomon, S. D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E., Shi, V., Bransford, T., Takeuchi, M., Gong, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61227-6 · Cited by 1,173
Self-citationPhenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction
Shah, S. J., Katz, D. H., Selvaraj, S., Burke, M. A., Yancy, C. W., Gheorghiade, M., Bonow, R. O., Huang, C.-C., & Deo, R. C. (2015) · Circulation · doi:10.1161/circulationaha.114.010637 · Cited by 1,157
Self-citationSemiparametric regression for the mean and rate functions of recurrent events
Lin, D. Y., Wei, L. J., Yang, I., & Ying, Z. (2000) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/1467-9868.00259 · Cited by 969
Mohammed, S. F., Hussain, S., Mirzoyev, S. A., Edwards, W. D., Maleszewski, J. J., & Redfield, M. M. (2015) · Circulation · doi:10.1161/circulationaha.114.009625 · Cited by 874
Self-citationImpaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction
Kraigher-Krainer, E., Shah, A. M., Gupta, D. K., Santos, A., Claggett, B., Pieske, B., Zile, M. R., Voors, A. A., Lefkowitz, M. P., Packer, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.052 · Cited by 756
Self-citationCleland, J. G. F., Bunting, K. V., Flather, M. D., Altman, D. G., Holmes, J., Coats, A. J. S., Manzano, L., McMurray, J. J. V., Ruschitzka, F., van Veldhuisen, D. J., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx564 · Cited by 659
Self-citationSolomon, S. D., Claggett, B., Lewis, E. F., Desai, A., Anand, I., Sweitzer, N. K., O'Meara, E., Shah, S. J., McKinlay, S., Fleg, J. L., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 532
Self-citationHeart Failure with Preserved Ejection Fraction
Redfield, M. M. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1511175 · Cited by 510
Self-citationGu, J., Noe, A., Chandra, P., Al‐Fayoumi, S., Ligueros‐Saylan, M., Sarangapani, R., Maahs, S., Ksander, G., Rigel, D. F., Jeng, A. Y., et al. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009343932 · Cited by 505
Shah, A. M., Claggett, B., Sweitzer, N. K., Shah, S. J., Anand, I. S., Liu, L., Pitt, B., Pfeffer, M. A., & Solomon, S. D. (2015) · Circulation · doi:10.1161/circulationaha.115.015884 · Cited by 478
Self-citationLeft Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction
Mohammed, S. F., Mirzoyev, S. A., Edwards, W. D., Dogan, A., Grogan, D. R., Dunlay, S. M., Roger, V. L., Gertz, M. A., Dispenzieri, A., Zeldenrust, S. R., et al. (2014) · JACC: Heart Failure · doi:10.1016/j.jchf.2013.11.004 · Cited by 448
Self-citationLund, L. H., Claggett, B., Liu, J., Lam, C. S., Jhund, P. S., Rosano, G. M., Swedberg, K., Yusuf, S., Granger, C. B., Pfeffer, M. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1149 · Cited by 430
Self-citationAngiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction
Solomon, S. D., Rizkala, A. R., Gong, J., Wang, W., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., et al. (2017) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.04.013 · Cited by 310
Self-citationThe Middle Child in Heart Failure: Heart Failure with Mid-Range Ejection Fraction (40–50%)
Lam, C. S. P., & Solomon, S. D. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.159 · Cited by 217
Self-citationAbdul‐Rahim, A. H., Shen, L., Rush, C. J., Jhund, P. S., Lees, K. R., & McMurray, J. J. V. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1160 · Cited by 75
Self-citationLam, C. S. P., & Solomon, S. D. (2017) · Circulation · doi:10.1161/circulationaha.117.027324 · Cited by 43
Self-citationCase 39-2016: A Man with a History of Prostate Cancer and Recent Rectal Bleeding
Hong, T. S., Allen, J. N., & Shellito, P. C. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1700703 · Cited by 6
Research works printed but not linked: 1
- Cowling BJ, Hutton JL, Shaw JEH. Joint modeling of event counts and sur- vival times. Appl Stat 2006; 55: 31-9.
Cited by
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationHeidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001063 · Cited by 4,922
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationMancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citation
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., Redfield, M. M., Rouleau, J. L., van Veldhuisen, D. J., Zannad, F., Zile, M. R., Desai, A. S., Claggett, B., Jhund, P. S., Boytsov, S. A., Comin-Colet, J., Cleland, J., Düngen, H.-D., Goncalvesova, E., Katova, T., Kerr Saraiva, J. F., Lelonek, M., Merkely, B., Senni, M., Shah, S. J., Zhou, J., Rizkala, A. R., Gong, J., Shi, V. C., & Lefkowitz, M. P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., M.A.P., A.S.D., B.C.); the British Heart Foundation Cardiovascular Research Centre (J.J.V.M., P.S.J.) and the Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Well-being (J.C.), University of Glasgow, Glasgow, and the National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London (J.C.) — all in the United Kingdom; University of...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Anand, Inder S.
- Ge, Junbo
- Lam, Carolyn S.P.
- Maggioni, Aldo P.
- Packer, Milton
- Pfeffer, Marc A.
- Pieske, Burkert
- Redfield, Margaret M.
- Rouleau, Jean L.
- Zannad, Faiez
- Zile, Michael R.
- Desai, Akshay S.
- Claggett, Brian
- Jhund, Pardeep S.
- Boytsov, Sergey A.
- Cleland, John
- Düngen, Hans-Dirk
- Lelonek, Małgorzata
- Senni, Michele
- Shah, Sanjiv J.
- Zhou, Jingmin
- Rizkala, Adel R.
- Gong, Jianjian
- Shi, Victor C.
- Lefkowitz, Martin P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-10-24
- Volume
- 381
- Issue
- 17
- Pages
- 1609-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2971294569
- Cited by
- 2,430
- References
- 25
- Citations by year
- 2026: 258 · 2025: 296 · 2024: 338 · 2023: 361 · 2022: 414 · 2021: 385 · 2020: 318 · 2019: 55
- FWCI
- 211.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Research Bank (Australian Catholic University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Novartis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- sacubitril/valsartan, valsartan, angiotensin receptor-neprilysin inhibition, heart failure with preserved ejection fraction, heart failure hospitalization, cardiovascular mortality, NYHA functional class, renal function, Kansas City Cardiomyopathy Questionnaire, natriuretic peptides, structural heart disease, drug safety, adverse events, anemia of chronic kidney disease, hyperkalemia
- MeSH terms
- Valsartan, Aged, Aminobutyrates, Angioedema, Biphenyl Compounds, Cardiovascular Diseases, Double-Blind Method, Drug Combinations, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Hypotension, Male, Middle Aged, Quality of Life, Sex Factors, Stroke Volume, Tetrazoles, Neprilysin, Single-Blind Method, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.